All In Biotech

Drug Trial Radar · NCT02430363

Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475

Phase IIb Trial Evaluations Of The Effectiveness Of Treatment Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 (Pembrolizumab)

Last checked: Nov 19, 2026Latest source record: Feb 24, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

58

Planned (sponsor's estimate)

Start

Mar 2013

Primary completion

Jan 2016

Study completion Jun 2018

Sponsor

Lead sponsor
Medical Research CouncilGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Aarhus University Hospital; NCRI Clinical Studies Groups; ECCO - the European CanCer Organisation; Merck Sharp & Dohme LLC
First posted
Apr 30, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

It is known that after application of MK-3475 activated PD -1 negatively regulates the activation of T cells through suppression of the path of PI3K / Akt. This study will identify the effectiveness of oral inhibitors of PI3K / Akt pathway in comparison with MK-3475 (pembrolizumab).

Conditions

  • Glioblastoma

Interventions

  • MK - 3475Drug

    Administered Intravenously

  • Suppressor of the PI3K/Akt pathwaysBiological

    Capsules orally with food

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free SurvivalTime frame: Time Frame: 12 months

Locations

13 sites in 10 countries. Site status is shown where the registry gives one.

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • M D Anderson Cancer Center

    Houston, Texas

  • UCL- Cliniques Universitaires Saint Luc

    Brussels, Belgium

  • St Johannes Hospital

    Duisburg, Germany

  • Spedali Civili di Brescia

    Brescia, Italy

  • IRCCS San Raffaele

    Milan, Italy

  • Lower-Silesian Oncology Centre

    Wroclaw, Lower Silesian Voivodeship, Poland

  • Pavlov State Medical University

    Saint Petersburg, Russia

  • Hospital Universitario Germans Trias I Pujol

    Barcelona, Spain

  • Universitätsklinik für Frauenheilkunde

    Bern, Switzerland

  • Regional Cancer Center

    Dnipro, Ukraine

  • National Institute of Cancer

    Kiev, Ukraine

  • Royal Victoria Hospital

    Belfast, Ulster, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.